Cirera Laia, Galatas Beatriz, Alonso Sergi, Paaijmans Krijn, Mamuquele Miler, Martí-Soler Helena, Guinovart Caterina, Munguambe Humberto, Luis Fabião, Nhantumbo Hoticha, Montañà Júlia, Bassat Quique, Candrinho Baltazar, Rabinovich Regina, Macete Eusebio, Aide Pedro, Alonso Pedro, Saúte Francisco, Sicuri Elisa
ISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
PLoS One. 2020 Jul 6;15(7):e0235631. doi: 10.1371/journal.pone.0235631. eCollection 2020.
As new combinations of interventions aiming at interrupting malaria transmission are under evaluation, understanding the associated economic costs and benefits is critical for decision-making. This study assessed the economic cost and cost-effectiveness of the Magude project, a malaria elimination initiative implemented in a district in southern Mozambique (i.e. Magude) between August 2015-June 2018. This project piloted a combination of two mass drug administration (MDA) rounds per year for two consecutive years, annual rounds of universal indoor residual spraying (IRS) and a strengthened surveillance and response system on the back of universal long-lasting insecticide treated net (LLIN) coverage and routine case management implemented by the National Malaria Control Program (NMCP). Although local transmission was not interrupted, the project achieved large reductions in the burden of malaria in the target district.
We collected weekly economic data, estimated costs from the project implementer perspective and assessed the incremental cost-effectiveness ratio (ICER) associated with the Magude project as compared to routine malaria control activities, the counterfactual. We estimated disability-adjusted life years (DALYs) for malaria cases and deaths and assessed the variation of the ICER over time to capture the marginal costs and effectiveness associated with subsequent phases of project implementation. We used deterministic and probabilistic sensitivity analyses to account for uncertainty and built an alternative scenario by assuming the implementation of the interventions from a governmental perspective. Economic costs are provided in constant US$2015.
After three years, the Magude project averted a total of 3,171 DALYs at an incremental cost of $2.89 million and an average yearly cost of $20.7 per targeted person. At an average cost of $19.4 per person treated per MDA round, the social mobilization and distribution of door-to-door MDA contributed to 53% of overall resources employed, with personnel and logistics being the main cost drivers. The ICER improved over time as a result of decreasing costs and improved effectiveness. The overall ICER was $987 (CI95% 968-1,006) per DALY averted, which is below the standard cost-effectiveness (CE) threshold of $1,404/DALY averted, three times the gross domestic product (GDP) per capita of Mozambique, but above the threshold of interventions considered highly cost-effective (one time the GDP per capita or $468/DALY averted) and above the recently suggested thresholds based on the health opportunity cost ($537 purchasing power parity/ DALY averted). A significantly lower ICER was obtained in the implementation scenario from a governmental perspective ($441/DALY averted).
Despite the initial high costs and volume of resources associated with its implementation, MDA in combination with other existing malaria control interventions, can be a cost-effective strategy to drastically reduce transmission in areas of low to moderate transmission in sub-Saharan Africa. However, further studies are needed to understand the capacity of the health system and financial affordability to scale up such strategies at regional or national level.
由于旨在阻断疟疾传播的新干预措施组合正在评估中,了解相关的经济成本和效益对于决策至关重要。本研究评估了马古德项目的经济成本和成本效益,该项目是2015年8月至2018年6月在莫桑比克南部一个地区(即马古德)实施的一项疟疾消除倡议。该项目连续两年每年试点两轮大规模药物喷洒(MDA),每年进行一轮室内滞留喷洒(IRS),并在国家疟疾控制项目(NMCP)实施的长效驱虫蚊帐(LLIN)普遍覆盖和常规病例管理基础上加强监测和应对系统。尽管当地传播未被阻断,但该项目使目标地区的疟疾负担大幅减轻。
我们收集了每周的经济数据,从项目实施者角度估算成本,并评估了与马古德项目相比常规疟疾控制活动(对照)的增量成本效益比(ICER)。我们估算了疟疾病例和死亡的伤残调整生命年(DALYs),并评估了ICER随时间的变化,以获取与项目实施后续阶段相关的边际成本和效益。我们使用确定性和概率敏感性分析来考虑不确定性,并通过假设从政府角度实施干预构建了一个替代方案。经济成本以2015年不变美元提供。
三年后,马古德项目共避免了3171个DALYs,增量成本为289万美元,平均每年每位目标人群成本为20.7美元。每轮MDA人均治疗成本为19.4美元,社会动员和挨家挨户的MDA分发占所用总资源的53%,人员和后勤是主要成本驱动因素。由于成本降低和效益提高,ICER随时间得到改善。总体ICER为每避免一个DALY987美元(CI95%968 - 1006),低于避免一个DALY的标准成本效益(CE)阈值1404美元,是莫桑比克人均国内生产总值的三倍,但高于被认为具有高成本效益的干预阈值(人均国内生产总值的一倍或每避免一个DALY468美元),且高于最近基于健康机会成本提出的阈值(537购买力平价/每避免一个DALY)。从政府角度的实施情景中获得了显著更低的ICER(每避免一个DALY441美元)。
尽管实施初期成本高昂且资源投入量大,但MDA与其他现有疟疾控制干预措施相结合,可能是在撒哈拉以南非洲低至中等传播地区大幅减少传播的一种具有成本效益的策略。然而,需要进一步研究以了解卫生系统的能力和财政承受能力,以便在区域或国家层面扩大此类策略。